Health Trials

Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer

1

Review clinical trials related to Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors/non-dysgerminomas, or glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC).

Participants needed: 392
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: BeOne MedicinesUpdated: Jun 3, 2026Locations: 46
Eligibility criteria

Hepatocellular carcinoma (HCC): Histologically or cytologically confirmed HCC th... [+8]

Prior therapy directed against glypican-3 (GPC3) or the T-cell costimulatory rec... [+5]

Read more